Literature DB >> 18199621

Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans.

Vibe G Frokjaer1, Lars H Pinborg, Jacob Madsen, Robin de Nijs, Claus Svarer, Aase Wagner, Gitte M Knudsen.   

Abstract

UNLABELLED: Imaging serotonin transporters in the living human brain is important in several fields, such as normal psychophysiology, mood disorders, eating disorders, and neurodegenerative disorders. The aim of this study was to compare different kinetic and semiquantitative methods for assessing serotonin transporters using (123)I-labeled 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM) in humans: an arterial plasma input model, simplified and Logan reference tissue models, and standardized uptake value ratios.
METHODS: Nine subjects were scanned with dynamic (123)I-ADAM SPECT (mean age, 31 y; range, 24-43 y), and metabolite-corrected arterial input was measured. Tissue reference models (simplified reference tissue model, Logan reference tissue model, and ratio method) were validated against the outcome of a 1-tissue-compartment model, and performance with decreasing scan length was evaluated. The specificity of (123)I-ADAM binding was investigated in a blocking experiment.
RESULTS: Binding estimates from the simplified reference tissue and Logan reference tissue models correlated tightly with full kinetic modeling when based on a 240- or 360-min dynamic acquisition (r = 0.99); however, there were slight underestimations (3%-5%), especially in high-binding regions. Application of the ratio method to data from 200 to 240 min overestimated specific binding (on average, by 10% +/- 28%) and correlated only moderately with estimates from the 1-tissue-compartment model (r = 0.94). With an acquisition time of 0-120 min, the Logan model still yielded an acceptable outcome when a fixed clearance rate constant (k2') from the cerebellum was applied. Intravenously injected citalopram was not associated with a decrease in cerebellar binding. A lipophilic metabolite that did not seem to bind specifically to serotonin transporter was seen in 2 of 7 subjects.
CONCLUSION: Serotonin transporter binding with (123)I-ADAM SPECT can be assessed with the Logan model based on a 120-min acquisition when a constant k2' is applied. This model, because it allows for more accurate and less biased binding estimates and thus reduces the required sample size, is advantageous over the ratio method used in clinical studies so far. A single blocking experiment supported the use of the cerebellum as a reference region.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199621     DOI: 10.2967/jnumed.107.046102

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

Review 1.  Radiotracers for the Central Serotoninergic System.

Authors:  Reynald Mangeant; Emmanuelle Dubost; Thomas Cailly; Valérie Collot
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-03

2.  The SPECT tracer [123I]ADAM binds selectively to serotonin transporters: a double-blind, placebo-controlled study in healthy young men.

Authors:  Elsmarieke van de Giessen; Jan Booij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

3.  Differences in serotonin transporter binding affinity in patients with major depressive disorder and night eating syndrome.

Authors:  J D Lundgren; J Amsterdam; A Newberg; K C Allison; N Wintering; A J Stunkard
Journal:  Eat Weight Disord       Date:  2009-03       Impact factor: 4.652

Review 4.  5-HT radioligands for human brain imaging with PET and SPECT.

Authors:  Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen
Journal:  Med Res Rev       Date:  2011-06-14       Impact factor: 12.944

Review 5.  The Emerging Role of SPECT Functional Neuroimaging in Schizophrenia and Depression.

Authors:  Anil Kalyoncu; Ali Saffet Gonul
Journal:  Front Psychiatry       Date:  2021-12-15       Impact factor: 4.157

6.  [11C]MADAM Used as a Model for Understanding the Radiometabolism of Diphenyl Sulfide Radioligands for Positron Emission Tomography (PET).

Authors:  Fabienne Gourand; Nahid Amini; Zhisheng Jia; Sharon Stone-Elander; Denis Guilloteau; Louisa Barré; Christer Halldin
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

7.  123I-ADAM SPET imaging of serotonin transporter in patients with epilepsy and comorbid depression.

Authors:  Maarika Liik; Malle Paris; Liina Vahter; Katrin Gross-Paju; Sulev Haldre
Journal:  BMC Neurol       Date:  2013-12-17       Impact factor: 2.474

8.  Improving quantitative dosimetry in (177)Lu-DOTATATE SPECT by energy window-based scatter corrections.

Authors:  Robin de Nijs; Vera Lagerburg; Thomas L Klausen; Søren Holm
Journal:  Nucl Med Commun       Date:  2014-05       Impact factor: 1.690

9.  Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder.

Authors:  K R Müller-Vahl; N Szejko; F Wilke; E Jakubovski; L Geworski; F Bengel; G Berding
Journal:  Sci Rep       Date:  2019-01-30       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.